title: Amplification of pulsatile glucagon counterregulation by switch-off of alpha-cell-suppressing signals in streptozotocin-treated rats.
abstract: Glucagon counterregulation (GCR) is a key protection against hypoglycemia that is compromised in diabetes via an unknown mechanism. To test the hypothesis that alpha-cell-inhibiting signals that are switched off during hypoglycemia amplify GCR, we studied streptozotocin (STZ)-treated male Wistar rats and estimated the effect on GCR of intrapancreatic infusion and termination during hypoglycemia of saline, insulin, and somatostatin. Times 10 min before and 45 min after the switch-off were analyzed. Insulin and somatostatin, but not saline, switch-off significantly increased the glucagon levels (P = 0.03), and the fold increases relative to baseline were significantly higher (P < 0.05) in the insulin and somatostatin groups vs. the saline group. The peak concentrations were also higher in the insulin (368 pg/ml) and somatostatin (228 pg/ml) groups vs. the saline (114 pg/ml) group (P < 0.05). GCR was pulsatile in most animals, indicating a feedback regulation. After the switch-off, the number of secretory events and the total pulsatile production were lower in the saline group vs. the insulin and somatostatin groups (P < 0.05), indicating enhancement of glucagon pulsatile activity by insulin and somatostatin compared with saline. Network modeling analysis demonstrates that reciprocal interactions between alpha- and delta-cells can explain the amplification by interpreting the GCR as a rebound response to the switch-off. The model justifies experimental designs to further study the intrapancreatic network in relation to the switch-off phenomenon. The results of this proof-of-concept interdisciplinary study support the hypothesis that GCR develops as a rebound pulsatile response of the intrapancreatic endocrine feedback network to switch-off of alpha-cell-inhibiting islet signals.
authors.affiliation: University of Virginia Health System, Charlottesville, VA 22908, USA. leon@virginia.edu
authors.forename: Leon S
authors.initials: LS
authors.lastname: Farhy
authors.forename: Zhongmin
authors.initials: Z
authors.lastname: Du
authors.forename: Qiang
authors.initials: Q
authors.lastname: Zeng
authors.forename: Paula P
authors.initials: PP
authors.lastname: Veldhuis
authors.forename: Michael L
authors.initials: ML
authors.lastname: Johnson
authors.forename: Kenneth L
authors.initials: KL
authors.lastname: Brayman
authors.forename: Anthony L
authors.initials: AL
authors.lastname: McCall
mesh_terms: D000465:Algorithms; D000818:Animals; D001786:Blood Glucose / Q000502:physiology; D003627:Data Interpretation, Statistical; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism / Q000503:physiopathology*; D025461:Feedback, Physiological; D005934:Glucagon / Q000378:metabolism / Q000502:physiology*; D050416:Glucagon-Secreting Cells / Q000187:drug effects / Q000502:physiology*; D006207:Half-Life; D006727:Hormone Antagonists / Q000494:pharmacology; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000502:physiology; D008297:Male; D015233:Models, Statistical; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D013004:Somatostatin / Q000494:pharmacology
chemical_list: D001786:Blood Glucose; D006727:Hormone Antagonists; D013004:Somatostatin; D005934:Glucagon